PSEN1 and Alzheimer disease: The proof in vivo that it is possible to counteract the toxicity exerted by a high Aβ burden by biological factors is found in a particular group of early-onset AD patients carrying the presenilin 1 (PSEN1) E280A mutation that increase Aβ production and induce amyloid accumulation in the brain.